Key Highlights

  • Laureate's Peruvian Subsidiary acquired UCAL for about $35 million.
  • The campus serves nearly 2,500 students and can accommodate about 5,000.
  • Third-quarter Revenue was $485.1 million, up 21% reported.
  • The company ended September with $189.9 million of cash and $14.3 million of net debt.

Laureate Education (NASDAQ:LAUR) has spent much of 2026 returning cash to shareholders, but a smaller transaction in Peru shows how management is also thinking about physical capacity. On November 5, 2026, the company said its Peruvian subsidiary, Universidad Peruana de Ciencias Aplicadas (UPC), had acquired Universidad de Ciencias y Artes de América Latina (UCAL) in Metropolitan Lima for about $35 million. For a Business whose growth depends on admitting more students each intake, the question of where those students sit matters. The deal is modest in size, yet it targets a constraint that management itself has identified.

Latest Company Context

According to the announcement, UPC bought all of UCAL's Capital Stock for roughly $35 million, a figure that includes campus real estate valued at about $25 million. The campus serves nearly 2,500 students and can accommodate about 5,000. Laureate said UPC has strong Demand in Metropolitan Lima but limited room to expand its existing campus, and that UCAL will become part of UPC after an integration process.

The purchase follows a solid third quarter. In its October 29 release, Laureate reported revenue of $485.1 million, up 21% reported and 14% in constant currency, and adjusted EBITDA of $146.8 million. Peru contributed $228.6 million of revenue and $94.0 million of adjusted EBITDA, with new enrollments up 10%. The company ended September with $189.9 million of cash and net Debt of only $14.3 million.

Key Business and index Drivers

Laureate operates only in Mexico and Peru, so each campus decision carries weight. In Peru, total enrollments reached 247,100 at September 30, up 5%, and the segment's revenue grew 7% in constant currency during the third quarter. If demand in Lima continues to exceed available seats, buying an existing licensed institution may offer a faster route to capacity than building from scratch, though integration of academic programs, staff and accreditation could take time and carry costs.

The price is small relative to Laureate's balance sheet: roughly $35 million compares with about $256 million spent on share repurchases in the first nine months of 2026 and a buyback authorization lifted by $150 million to about $225.2 million. That balance suggests management sees room for both bolt-on Investment and capital returns. Currency remains a swing factor, since results are reported in dollars while revenue is earned in pesos and soles.

What Investors Should Watch

The next formal checkpoint is fourth-quarter and full-year 2026 reporting, likely in early 2027, when management may describe how UCAL is being folded into UPC and whether its students are counted in enrollment totals. The reaffirmed 2026 outlook calls for revenue of $1.920 billion to $1.930 billion, adjusted EBITDA of $593 million to $599 million and total enrollments of 518,000 to 523,000.

Laureate also expects calendar timing effects that helped the third quarter, about $29 million of revenue and $26 million of adjusted EBITDA, to reverse in the fourth quarter. The Peruvian academic year typically begins in the first quarter, so early-2027 intake figures could offer the first evidence of whether added Lima capacity translates into more new students. Investors may also watch the pace of Buybacks under the expanded authorization.

Capacity Behind Peru Growth

The UCAL purchase is not large enough to change Laureate's financial profile on its own, but it addresses a stated bottleneck in the company's most profitable segment. Whether the added seats lift intake will depend on integration, demand in Lima and the competitive response from other private universities. With a low-debt Balance Sheet and an active buyback, Laureate appears to have flexibility to pursue similar steps. Upcoming results and the 2027 intake cycle could show how much capacity, rather than demand, has been limiting growth.